aTyr Pharma (NASDAQ:ATYR) Posts Quarterly Earnings Results, Misses Expectations By $3.43 EPS

aTyr Pharma (NASDAQ:ATYR) announced its quarterly earnings data on Thursday. The company reported ($7.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($4.00) by ($3.43), FiscalAI reports. The company had revenue of $235.23 million during the quarter, compared to analysts’ expectations of $2.50 million.

aTyr Pharma Stock Up 5.3%

ATYR stock traded up $0.32 during trading on Friday, reaching $6.35. 66,192 shares of the company’s stock were exchanged, compared to its average volume of 83,642. aTyr Pharma has a 1-year low of $4.07 and a 1-year high of $44.40. The company’s fifty day moving average price is $11.68 and its 200-day moving average price is $23.59. The firm has a market cap of $15.56 million, a PE ratio of -0.29 and a beta of 1.04.

Analyst Ratings Changes

A number of brokerages recently commented on ATYR. Wells Fargo & Company upped their price objective on aTyr Pharma from $1.00 to $4.00 and gave the stock an “equal weight” rating in a research note on Friday. Royal Bank Of Canada cut their target price on aTyr Pharma to $6.00 and set a “sector perform” rating on the stock in a research note on Friday. Weiss Ratings downgraded shares of aTyr Pharma from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, September 16th. Finally, Wall Street Zen upgraded shares of aTyr Pharma to a “hold” rating in a research report on Saturday, October 31st. One analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, aTyr Pharma presently has an average rating of “Hold” and a consensus target price of $5.00.

aTyr Pharma Company Profile

aTyr Pharma, Inc (NASDAQ:ATYR) is a biotechnology company focused on developing therapies that modulate immune system activity. The company’s research is based on a class of naturally occurring proteins known as extracellular tRNA synthetases, which can influence biological processes involved in inflammation, tissue repair and immune regulation.

aTyr’s lead product candidate is efzofitimod, an engineered protein therapeutic designed to target neuropilin-2 and regulate immune responses in the lungs.